Corium International Inc (CORI) Hit 52-Week High

September 12, 2017 - By Darrin Black

Investors sentiment increased to 0.86 in Q4 2016. Its up 0.17, from 0.69 in 2016Q3. It is positive, as 5 investors sold Corium International Inc shares while 9 reduced holdings. 4 funds opened positions while 8 raised stakes. 9.28 million shares or 50.34% less from 18.69 million shares in 2016Q3 were reported.
220,000 are held by Fmr Lc. Blackrock Institutional Tru Na invested in 0% or 66,313 shares. Tci Wealth Advsrs holds 162 shares or 0% of its portfolio. Blackrock Invest Mngmt Lc has 0% invested in Corium International Inc (NASDAQ:CORI). Prelude Cap Management Lc stated it has 17,881 shares or 0.01% of all its holdings. Northern Trust Corp reported 19,304 shares or 0% of all its holdings. Essex Inv Management Lc holds 101,655 shares or 0.07% of its portfolio. Franklin Res Incorporated has 0% invested in Corium International Inc (NASDAQ:CORI). Wells Fargo & Mn has invested 0% in Corium International Inc (NASDAQ:CORI). The Massachusetts-based Panagora Asset Mngmt Inc has invested 0% in Corium International Inc (NASDAQ:CORI). 1,783 were accumulated by Parallax Volatility Advisers L P. Moreover, Victory Mngmt has 0% invested in Corium International Inc (NASDAQ:CORI). The Pennsylvania-based Vanguard Gru has invested 0% in Corium International Inc (NASDAQ:CORI). Putnam Invs Llc accumulated 29,055 shares. Broadfin Cap Limited Com accumulated 1.92M shares or 0.87% of the stock.

The stock of Corium International Inc (NASDAQ:CORI) hit a new 52-week high and has $10.99 target or 9.00 % above today’s $10.08 share price. The 6 months bullish chart indicates low risk for the $360.29 million company. The 1-year high was reported on Sep, 12 by If the $10.99 price target is reached, the company will be worth $32.43 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 83,074 shares traded. Corium International Inc (NASDAQ:CORI) has risen 84.14% since September 12, 2016 and is uptrending. It has outperformed by 67.44% the S&P500.

Corium International Inc (NASDAQ:CORI) Ratings Coverage

Among 6 analysts covering Corium International (NASDAQ:CORI), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Corium International had 13 analyst reports since August 25, 2015 according to SRatingsIntel. Needham maintained the shares of CORI in report on Monday, November 16 with “Buy” rating. On Tuesday, August 25 the stock rating was downgraded by Zacks to “Buy”. As per Wednesday, September 2, the company rating was upgraded by Zacks. Jefferies maintained it with “Buy” rating and $1000 target in Monday, August 7 report. The stock of Corium International Inc (NASDAQ:CORI) earned “Buy” rating by Needham on Tuesday, February 9. The rating was downgraded by WBB Securities to “Hold” on Monday, August 31. The stock of Corium International Inc (NASDAQ:CORI) has “Buy” rating given on Monday, July 17 by Jefferies. The stock of Corium International Inc (NASDAQ:CORI) has “Buy” rating given on Friday, May 26 by Jefferies.

More notable recent Corium International Inc (NASDAQ:CORI) news were published by: which released: “Corium to Report Third Quarter Fiscal 2017 Financial Results on Thursday …” on July 27, 2017, also with their article: “Corium International: Room to Run?” published on June 29, 2017, published: “Corium International Has A New Take On A Great Drug” on May 01, 2017. More interesting news about Corium International Inc (NASDAQ:CORI) were released by: and their article: “Corium to Present Clinical Results from Pilot Bioequivalence Study of Once …” published on July 06, 2017 as well as‘s news article titled: “Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex …” with publication date: July 18, 2017.

Corium International, Inc. is a commercial-stage biopharmaceutical firm focused on the development, manufacture and commercialization of specialty pharmaceutical products. The company has market cap of $360.29 million. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. It currently has negative earnings. The Firm has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.